NEW YORK (GenomeWeb News) — Bayer Schering Pharma has renewed its licenses for GeneGo’s MetaCore software and databases, GeneGo said today.
St. Joseph, Mich.-based GeneGo said that Bayer Schering Pharma has agreed to another three-year license for the software, which is designed for use in target selection and validation, data mining, and for identifying biomarkers for disease states and toxicology. Bayer Schering Pharma is using the software in its oncology, cardiology, and women’s health programs, GeneGo VP of Business Development Julie Bryant said in a statement.
GeneGo also said it is currently developing disease-specific platforms for cancer and cardiovascular studies that “blueprint pathway maps for the disease, processes and mechanisms as well as offering public domain experimental data and disease ontologies.”
Financial terms of the agreement were not released.